Hyundai Pharm
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, a… Read more
Hyundai Pharm (004310) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of May 2025: -0.038x
Based on the latest financial reports, Hyundai Pharm (004310) has a cash flow conversion efficiency ratio of -0.038x as of May 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.99 Billion) by net assets (₩77.99 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hyundai Pharm - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Hyundai Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hyundai Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hyundai Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Japan Cash Machine Co. Ltd
F:JCM
|
-0.019x |
|
Trimegah Securities Tbk
JK:TRIM
|
-0.199x |
|
Power Wind Health Industry Incorporated
TW:8462
|
0.239x |
|
Beijing Liven Technology Co. Ltd.
SHE:001259
|
0.006x |
|
Magellan Aerospace Corporation
PINK:MALJF
|
0.006x |
|
Tavia Acquisition Corp. Ordinary Shares
NASDAQ:TAVI
|
-0.001x |
|
Berkeley Energia Ltd
AU:BKY
|
0.000x |
|
Namsun Alumini
KO:008350
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Hyundai Pharm (2010–2024)
The table below shows the annual cash flow conversion efficiency of Hyundai Pharm from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | ₩79.07 Billion | ₩-2.37 Billion | -0.030x | +44.10% |
| 2023-11-30 | ₩84.66 Billion | ₩-4.55 Billion | -0.054x | -139.98% |
| 2022-11-30 | ₩86.56 Billion | ₩11.62 Billion | 0.134x | +126.60% |
| 2021-11-30 | ₩86.60 Billion | ₩5.13 Billion | 0.059x | -50.56% |
| 2020-11-30 | ₩90.14 Billion | ₩10.80 Billion | 0.120x | +50.79% |
| 2019-11-30 | ₩87.58 Billion | ₩6.96 Billion | 0.079x | +200.09% |
| 2018-11-30 | ₩107.00 Billion | ₩2.83 Billion | 0.026x | +231.16% |
| 2017-11-30 | ₩98.10 Billion | ₩-1.98 Billion | -0.020x | +26.42% |
| 2016-11-30 | ₩100.08 Billion | ₩-2.75 Billion | -0.027x | -134.94% |
| 2013-11-30 | ₩101.21 Billion | ₩7.95 Billion | 0.079x | +390.34% |
| 2012-11-30 | ₩99.69 Billion | ₩-2.70 Billion | -0.027x | -145.03% |
| 2011-11-30 | ₩104.32 Billion | ₩6.27 Billion | 0.060x | +107.53% |
| 2010-11-30 | ₩92.50 Billion | ₩2.68 Billion | 0.029x | -- |